Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia.

ABSTRACT: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies arising from the bone marrow. Despite recent advances in treating these diseases, patients with higher-risk MDS and AML continue to have a poor prognosis with limited survival. It has long been recognized that there is an immune component to the pathogenesis of MDS and AML, but until recently, immune therapies have played a limited role in treating these diseases. Immune suppressive therapy exhibits durable clinical responses in selected patients with MDS, but the question of which patients are most suitable for this treatment remains unclear. Over the past decade, there has been remarkable progress in identifying genomic features of MDS and AML, which has led to an improved discernment of the mol

SUBMITTER: Kapoor S 

PROVIDER: S-EPMC8507987 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature